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Summary
Background HIV-1 infection is associated with increased risk of tuberculosis and a safe and eﬀ ective vaccine would 
assist control measures. We assessed the safety, immunogenicity, and eﬃ  cacy of a candidate tuberculosis vaccine, 
modiﬁ ed vaccinia virus Ankara expressing antigen 85A (MVA85A), in adults infected with HIV-1.
Methods We did a randomised, double-blind, placebo-controlled, phase 2 trial of MVA85A in adults infected with 
HIV-1, at two clinical sites, in Cape Town, South Africa and Dakar, Senegal. Eligible participants were aged 
18–50 years, had no evidence of active tuberculosis, and had baseline CD4 counts greater than 350 cells per μL if they 
had never received antiretroviral therapy or greater than 300 cells per μL (and with undetectable viral load before 
randomisation) if they were receiving antiretroviral therapy; participants with latent tuberculosis infection were 
eligible if they had completed at least 5 months of isoniazid preventive therapy, unless they had completed treatment 
for tuberculosis disease within 3 years before randomisation. Participants were randomly assigned (1:1) in blocks of 
four by randomly generated sequence to receive two intradermal injections of either MVA85A or placebo. 
Randomisation was stratiﬁ ed by antiretroviral therapy status and study site. Participants, nurses, investigators, and 
laboratory staﬀ  were masked to group allocation. The second (booster) injection of MVA85A or placebo was given 
6–12 months after the ﬁ rst vaccination. The primary study outcome was safety in all vaccinated participants (the 
safety analysis population). Safety was assessed throughout the trial as deﬁ ned in the protocol. Secondary outcomes 
were immunogenicity and vaccine eﬃ  cacy against Mycobacterium tuberculosis infection and disease, assessed in the 
per-protocol population. Immunogenicity was assessed in a subset of participants at day 7 and day 28 after the ﬁ rst 
and second vaccination, and M tuberculosis infection and disease were assessed at the end of the study. The trial is 
registered with ClinicalTrials.gov, number NCT01151189.
Findings Between Aug 4, 2011, and April 24, 2013, 650 participants were enrolled and randomly assigned; 649 were 
included in the safety analysis (324 in the MVA85A group and 325 in the placebo group) and 645 in the per-protocol 
analysis (320 and 325). 513 (71%) participants had CD4 counts greater than 300 cells per μL and were receiving 
antiretroviral therapy; 136 (21%) had CD4 counts above 350 cells per μL and had never received antiretroviral 
therapy. 277 (43%) had received isoniazid prophylaxis before enrolment. Solicited adverse events were more 
frequent in participants who received MVA85A (288 [89%]) than in those given placebo (235 [72%]). 34 serious 
adverse events were reported, 17 (5%) in each group. MVA85A induced a signiﬁ cant increase in antigen 85A-speciﬁ c 
T-cell response, which peaked 7 days after both vaccinations and was primarily monofunctional. The number of 
participants with negative QuantiFERON-TB Gold In-Tube ﬁ ndings at baseline who converted to positive by the 
end of the study was 38 (20%) of 186 in the MVA85A group and 40 (23%) of 173 in the placebo group, for a vaccine 
eﬃ  cacy of 11·7% (95% CI –41·3 to 44·9). In the per-protocol population, six (2%) cases of tuberculosis disease 
occurred in the MVA85A group and nine (3%) occurred in the placebo group, for a vaccine eﬃ  cacy of 32·8% 
(95% CI –111·5 to 80·3).
Interpretation MVA85A was well tolerated and immunogenic in adults infected with HIV-1. However, we detected no 
eﬃ  cacy against M tuberculosis infection or disease, although the study was underpowered to detect an eﬀ ect against 
disease. Potential reasons for the absence of detectable eﬃ  cacy in this trial include insuﬃ  cient induction of a vaccine-
induced immune response or the wrong type of vaccine-induced immune response, or both.
Funding European & Developing Countries Clinical Trials Partnership (IP.2007.32080.002), Aeras, Bill & Melinda 
Gates Foundation, Wellcome Trust, and Oxford-Emergent Tuberculosis Consortium.
Copyright © Ndiaye et al. Open Access article distributed under the terms of CC BY.
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Introduction
Tuberculosis is a substantial global cause of mortality 
and morbidity, with 9 million new cases of active 
tuberculosis and 1·5 million deaths occurring in 2013.1 
One third of the world’s population is infected with 
Mycobacterium tuberculosis.1 HIV-1 co-infection is one of 
the most important risk factors for both infection with 
M tuberculosis and active tuberculosis disease,2 with an 
estimated 1·1 million of all new tuberculosis cases in 
2013 occurring in people co-infected with HIV-1.1 The 
WHO African region accounts for 80% of HIV-1-
associated tuberculosis.1 Additionally, the growing 
incidence of drug-resistant tuberculosis is associated 
with poor treatment outcome and increased mortality.3 
The global Stop TB Partnership aims to eliminate 
tuberculosis as a public health problem by 2050. An 
agreed major component to advance this aim would be 
an eﬀ ective vaccine.4 BCG is the only licensed 
tuberculosis vaccine—it provides protection against 
severe childhood tuberculosis,5,6 but the protection 
conferred against pulmonary tuberculosis in adults and 
adolescents is highly variable.7,8
At least 16 candidate tuberculosis vaccines have 
advanced to clinical testing.9 The modiﬁ ed vaccinia virus 
Ankara expressing the major M tuberculosis antigen 85A 
(MVA85A) is a clinically advanced candidate vaccine.10–12 
MVA85A is well tolerated and immunogenic in adults 
infected and not infected with HIV-1, and in infants not 
exposed to HIV-1.10–14 MVA85A adds to BCG-induced 
protection against mycobacterial challenge in some 
preclinical animal models.15–19 However, boosting BCG 
with MVA85A in South African infants not infected with 
HIV-1 did not confer additional protection against 
tuberculosis disease or M tuberculosis infection.10
Administration of several doses of the saprophyte 
Mycobacterium vaccae to adults infected with HIV-1 was 
associated with a decreased risk of protocol-deﬁ ned 
pulmonary tuberculosis,20 suggesting that vaccination 
might be eﬀ ective in people infected with HIV-1. Here we 
report the results of a multisite, randomised, placebo-
controlled, phase 2 trial to assess the safety, 
immunogenicity, and eﬃ  cacy of MVA85A in healthy 
adults infected with HIV-1.
Methods
Study design and participants
We did a proof-of-concept, randomised, double-blind, 
placebo-controlled, phase 2 trial of MVA85A at two 
clinical sites, in Cape Town, South Africa and Dakar, 
Senegal. In Cape Town, participants were recruited in the 
community and from primary care clinics in Khayelitsha 
by use of radio and newspaper advertisements, ﬂ yers, 
pamphlets, and information campaigns at the clinics. 
Khayelitsha is a densely populated, low-income, peri-
urban township. In 2010, antenatal HIV-1 prevalence was 
33% and the tuberculosis case notiﬁ cation rate was at 
least 1500 per 100 000 population per year.21 In Dakar, 
participants were recruited from public service HIV 
clinics at the Centre de Traitement Ambulatoire and the 
Centre de Recherche Clinique et de Formation, Centre 
Hospitalier Universitaire de Fann. Senegal had an 
estimated HIV-1 prevalence in adults of less than 1% in 
2012, and a reported tuberculosis incidence rate of 0·14% 
in 2013.1 The annual rate of M tuberculosis infection has 
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Research in context
Evidence before this study
One previous study assessed the eﬃ  cacy of several doses of the 
saprophyte Mycobacterium vaccae against tuberculosis disease in 
adults infected with HIV-1, and showed a decreased risk of 
protocol-deﬁ ned pulmonary tuberculosis. A previous study with 
the MVA85A, the candidate vaccine under assessment here, has 
showed that boosting with MVA85A did not enhance protective 
eﬃ  cacy in BCG-vaccinated infants. Adults infected with HIV-1 are 
an important target population for a new tuberculosis vaccine, 
and in earlier studies, vaccine-induced immunogenicity in adults 
infected with HIV-1 was higher than in infants.
Added value of this study
This is the ﬁ rst time that a candidate tuberculosis vaccine has 
been assessed for eﬃ  cacy against Mycobacterium tuberculosis 
infection in people infected with HIV-1. The results show that 
vaccinating adults infected with HIV-1 with MVA85A is safe, but 
does not confer protection against infection with M tuberculosis.
Implications of all the available evidence
The safety of MVA85A in this large study population of 
adults with HIV infection is an important finding for 
tuberculosis vaccine development. The vector is safe to give 
to people without HIV testing; these safety data provide 
some generic reassurance that new candidate tuberculosis  
vaccines are safe in this higher risk population. Additionally, 
this study has shown that high-quality, multicentre 
tuberculosis vaccine trials in vulnerable populations are 
possible. The absence of efficacy despite immunogenicity in 
this and previous clinical trials of MVA85A suggests that the 
current parameters for selection of tuberculosis vaccine 
candidates are inadequate. Standardised preclinical animal 
models that better represent human infection and disease, 
and a greater understanding of immune mechanisms of 
protection in human tuberculosis are both urgently needed. 
Alternative approaches to vaccine development, including 
the delivery of candidate vaccines direct to the respiratory 
mucosa, merit assessment. Other lessons learnt from this 
trial include the characterisation of the epidemiology of 
M tuberculosis infection and disease associated with HIV-1 
infection in a setting of antiretroviral therapy and isoniazid 
chemoprophylaxis.
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not previously been estimated at either site. Eligibility 
criteria included participants aged 18–50 years with no 
evidence of active tuberculosis, and baseline CD4 counts 
greater than 350 cells per μL if they were not receiving 
antiretroviral therapy, or greater than 300 cells per μL 
(and with undetectable viral load before randomisation) 
if they were receiving antiretroviral therapy. Participants 
with latent tuberculosis infection were eligible for 
enrolment if they had completed at least 5 months of 
isoniazid preventive therapy, unless they had completed 
treatment for tuberculosis disease within 3 years before 
randomisation. The complete inclusion criteria are listed 
in the study protocol (appendix).
The trial adhered to International Conference on 
Harmonisation Good Clinical Practice guidelines, and 
was approved by the University of Cape Town’s Faculty of 
Health Sciences Human Research Ethics Committee and 
the Medicines Control Council of South Africa; the 
Senegalese National Ethics Committee for Research in 
Health; and the Oxford University Tropical Research 
Ethics Committee. All participants provided written 
informed consent before any study procedure.
Randomisation and masking
Participants were randomly assigned (1:1) in blocks of 
four by a randomly generated sequence of participant 
identiﬁ cation numbers via an interactive voice response 
system to receive two intradermal injections of either 
1 × 10⁸ pfu MVA85A or placebo (Candida skin test antigen 
[Candin], Allermed Laboratories, San Diego, CA, USA). 
Randomisation was stratiﬁ ed by antiretroviral therapy 
status and study site. A statistician uninvolved with study 
analyses prepared the interactive voice response system 
randomisation schedule. Doses of vaccines were 
prepared and labelled in masked syringes by a pharmacist 
unmasked to group allocation. Participants, nurses (who 
were involved in assessment and follow-up), investigators, 
and laboratory staﬀ  were masked to group allocation. 
The second (booster) injection of MVA85A or placebo 
was given 6–12 months after the ﬁ rst vaccination and 
participants were actively followed up every 3 months 
until the last participant enrolled had completed 
6 months of follow-up after the booster vaccination.
Procedures
We collected data for the incidence of solicited and 
unsolicited adverse events, including both local injection-
site reactions and systemic reactions. Participants 
reported solicited adverse events on diary cards for 7 days 
after each vaccination and in response to direct 
questioning by trained study staﬀ  on days 7 and 28 after 
each injection. Phlebotomy for routine haematological 
and biochemical analysis was done at screening, before 
booster vaccination, and on days 7 and 28 after each 
vaccination. Peripheral CD4 cell count and HIV-1 viral 
load were also measured at these timepoints and every 
3 months until 6 months after booster vaccination. 
Serious adverse events were monitored by active 
surveillance throughout and until the end of the trial. 
The site investigators and local medical monitors 
determined the severity and seriousness of adverse 
events and the relation of these to the vaccine. 
An independent data monitoring committee assessed 
masked group safety data after 200 participants had been 
enrolled and unmasked after 600 participants had been 
enrolled.
In a prespeciﬁ ed subset of 70 participants (35 from 
each group), immunology samples were obtained before 
each vaccination and on days 7 and 28 after each 
vaccination. All immunology tests were done masked to 
group allocation. We assessed vaccine immunogenicity 
with three assays. First, ex vivo interferon γ enzyme-
linked immunospot (ELISPOT) analysis was done on 
fresh peripheral blood mononuclear cells.22 Cells were 
stimulated overnight with a single pool of 66 peptides of 
the antigen 85A (Ag85A), ESAT-6, and CFP-10. Second, 
Ag85A-speciﬁ c intracellular cytokine staining assay was 
done on whole blood.23 Stimulated ﬁ xed whole blood 
samples were stained for CD3-positive, CD4-positive, 
CD8-positive, CD14-positive, and CD19-positive cells, 
interferon γ, tumour necrosis factor α, interleukin 17, 
and interleukin 2. Third, Ag85A-speciﬁ c antibody 
response was measured on plasma. Ag85A-speciﬁ c 
immunoglobulin G (IgG) antibodies were measured by 
ELISA on eight serial two-fold dilutions of plasma 
(1:25–1:3200), by use of aﬃ  nity puriﬁ ed recombinant, 
histidine-tagged Ag85A24 (microwell plates coated with 
50 ng per well of recombinant Ag85A in borate buﬀ er, 
overnight at 4°C). Alkaline phosphatase-labelled goat 
anti-human IgG (Sigma, St Louis, MO, USA) was used 
as secondary antibody at a dilution of 1:1000 and optical 
density was read at 405 nm after development with 
phosphatase substrate (Sigma). Results were expressed 
in arbitrary units per mL (AU/mL), as compared with 
values of an internal tuberculosis serum standard of 
2500 AU/mL.
Participants were screened to exclude active 
tuberculosis by symptom screen and chest radiography 
at both sites before enrolment. In Cape Town, participants 
also underwent sputum collection for tuberculosis smear 
microscopy, GeneXpert MTB/RIF (Cepheid, Sunnyvale, 
CA, USA), and mycobacterial liquid culture (MGIT; 
Becton Dickinson, Sparks, MD, USA) because of 
previously documented high frequencies of asymp-
tomatic disease at this site.25 Latent M tuberculosis 
infection was deﬁ ned as either a positive QuantiFERON-
TB Gold In-Tube (QFT) test or a tuberculin puriﬁ ed 
protein derivative skin test (tuberculin skin test) reaction 
greater than 5 mm.
Participants were monitored throughout the trial for 
possible tuberculosis. Tuberculosis investigations were 
done in participants who had been in contact with a 
known case of active tuberculosis, in those who presented 
with at least one of cough for more than 1 week, fever for 
Articles
4 www.thelancet.com/respiratory   Published online February 26, 2015   http://dx.doi.org/10.1016/S2213-2600(15)00037-5
more than 1 week, drenching night sweats, unintentional 
weight loss of more than 3 kg, pleuritic chest pains, 
haemoptysis, or shortness of breath; and in those who 
converted to a positive QFT or tuberculin skin test 
(≤5 mm to >5 mm). Investigations included clinical 
examination, chest radiography, and collection of at least 
two sputum samples on which tuberculosis smear 
microscopy, GeneXpert MTB/RIF, and mycobacterial 
liquid culture were done. Chest radiographs were 
reviewed by two physicians, with a third reading to 
achieve consensus in the event of disagreement. QFT and 
tuberculin skin tests were repeated at the ﬁ nal study visit. 
Outcomes
Tuberculosis disease endpoint 1 was deﬁ ned as culture or 
GeneXpert MTB/RIF positivity; endpoint 2 included 
endpoint 1 and a composite clinical endpoint (which 
included a single acid-fast bacilli smear from a sterile body 
site; two smears from pulmonary and gastric sampling, 
and compatible clinical symptoms and radiological signs); 
and endpoint 3 was participant commencement on anti-
tubercular chemotherapy (see the study protocol for more 
information; appendix). The M tuberculosis infection 
endpoint was deﬁ ned as conversion from negative QFT at 
baseline to positive QFT at the ﬁ nal visit.
The primary study outcome was the safety of MVA85A 
in all participants who received at least one dose of study 
vaccine or placebo (the safety analysis population) as 
determined by the numbers and percentages of adverse 
events (including solicited, unsolicited, and serious 
adverse events).
The secondary outcome was the eﬃ  cacy of MVA85A 
for the prevention of active tuberculosis in the per-
protocol population (all randomly allocated participants 
who received at least one dose of study vaccine or placebo 
and had no major protocol deviations and no tuberculosis 
case deﬁ nition endpoints within 28 days after study 
day 0 [ﬁ rst vaccination]), which was determined by the 
incidence of active tuberculosis meeting the deﬁ nition of 
endpoint 1, calculated as the number of new cases of 
active tuberculosis with a date of diagnosis from 28 days 
after the ﬁ rst vaccination until the end of the study 
follow-up (May 19, 2014). An intention-to-treat analysis 
was also done for disease eﬃ  cacy.  In the per-protocol 
population, we also examined the eﬃ  cacy of MVA85A by 
antiretroviral therapy status at the time of randomisation 
and by baseline isoniazid preventive therapy status.
Other secondary outcomes were to assess CD4-positive 
lymphocyte counts and HIV-1 viral load before and after 
administration of MVA85A compared with placebo; to 
assess the immunogenicity of MVA85A compared with 
placebo as measured by the ex-vivo interferon γ ELISPOT 
assay; to assess the immunogenicity of MVA85A 
compared with placebo as measured by ﬂ ow cytometric 
intracellular cytokine staining of CD4-positive and CD8-
positive T cells after stimulation with a peptide pool of 
mycobacterial antigens; to identify potential 
immuno logical correlates of protection from tuberculosis 
in participants vaccinated with MVA85A and to assess 
the QFT conversion rate at ﬁ nal study assessment in 
MVA85A recipients compared with controls without a 
diagnosis of tuberculosis during the trial.
Statistical analysis
All sample size calculations assumed a loss to follow-up 
and death rate of 2%. The initial planned sample size for 
this trial was 1400 adult participants, to be followed up for 
2 years after the last participant was enrolled. This sample 
size provided 80% power to detect a vaccine eﬃ  cacy of 
60% against tuberculosis disease. However, after review of 
the phase 2 infant eﬃ  cacy data,10 the trial design was 
revised with safety as the primary objective and a smaller 
sample size and shorter follow-up of a minimum of 
6 months. The revised sample size for this study was 
selected as adequate for a review of the safety proﬁ le. With 
325 participants assigned to receive MVA85A, the revised 
sample would have a 90% probability of detecting at least 
one adverse event occurring at a rate of 0·71%. Because of 
the expected eﬀ ect of antiretroviral therapy on tuberculosis 
disease, an estimated tuberculosis disease incidence 
ranging between 1·5% and 2% per year was used to 
estimate the power of the revised sample size for eﬃ  cacy. 
Calculations were based on a one-sided log-rank test at a 
signiﬁ cance level of 0·10 and assumed completion of 
enrolment in 21 months, a follow-up period of about 
15 months for the last patient enrolled, and a maximum of 
36 months for the ﬁ rst patient enrolled. If the true eﬃ  cacy 
was about 70%, 325 patients per treatment group 
(650 patients total) provided 81% power to show positive 
eﬃ  cacy given an incidence rate of 2·0% in the control 
group per year, or 71% power given an incidence rate of 
1·5% in the control group per year. At a true eﬃ  cacy of 
about 60%, 325 patients per treatment group provided 
67% power to show positive eﬃ  cacy given an incidence 
rate of 2·0% per year, or 57% power given an incidence 
rate of 1·5% per year. Vaccine eﬃ  cacy to prevent infection 
was a secondary endpoint: the recorded QFT conversion 
rate in the study provided 80% power to detect a vaccine 
eﬃ  cacy of 50%.
Statistical analyses were done using SAS version 9.2. 
All analyses were prespeciﬁ ed in the statistical analysis 
plan before locking of the database. For the safety 
analysis, we compared the proportion of participants 
with at least one adverse event in the MVA85A group 
versus those in the placebo using Fisher’s exact test. We 
also calculated two-sided 95% CIs for proportions of 
adverse events within treatment groups and the 
diﬀ erences between groups.
The main statistical method used in the analysis of 
tuberculosis disease endpoints 1–3 was vaccine eﬃ  cacy, 
estimated as 1 minus the estimated hazard ratio, based on 
a Cox regression analysis of time (days) to initial 
tuberculosis diagnosis, based on the per-protocol 
population. As supportive conﬁ rmatory analysis, we used 
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the conditional binomial (Clopper-Pearson) method to 
estimate vaccine eﬃ  cacy and its corresponding two-sided 
95% CIs and p values. Time to initial diagnosis for each 
endpoint was compared by use of a two-sided log-rank 
test, stratiﬁ ed by study site and antiretroviral therapy 
status at randomisation. Analyses were summarised by 
antiretroviral therapy and treatment group for participants 
in the per-protocol population. Vaccine eﬃ  cacy against 
M tuberculosis infection and the corresponding 95% CI, 
and p value were calculated with  the conditional binomial 
method (Clopper-Pearson), identical to the tuberculosis 
case deﬁ nition endpoint analysis.
Other secondary endpoints were analysed in various 
ways. Median CD4 cell counts and associated two-sided 
95% CIs were summarised by antiretroviral therapy 
status at randomisation, study site, treatment group, and 
timepoint. HIV-1 viral load (copies per mL) was 
summarised with medians (and associated 95% CIs) by 
antiretroviral therapy status at randomisation, study site, 
and treatment group, at each available timepoint. Both 
the CD4 cell counts and HIV-1 viral load values were 
log-transformed before any analysis was done. We used 
Wilcoxon paired analysis to compare within group before 
and after vaccination responses.
Quintiles (Blomfontein, South Africa) did the statistical 
analysis, and Aeras paid for this service. The trial was 
registered with ClinicalTrials.gov, number NCT01151189.
Role of the funding source
Aeras was the trial sponsor and contributed to study 
design and data analysis. The other funders had no role 
in study design, data collection, data analysis, data 
interpretation, or writing of the report. BPN, FT, BSL, 
RJW, and HM had full access to all the data in the study. 
HM had ﬁ nal responsibility for the decision to submit for 
publication.
Results
Between Aug 4, 2011, and April 24, 2013, 1233 adults 
infected with HIV-1 were screened and 650 were 
randomly assigned; 649 were included in the safety 
analysis and 645 in the per-protocol analysis (ﬁ gure 1). 
513 (71%) participants had CD4 counts greater than 
300 cells per μL and were receiving antiretroviral 
Figure 1: Trial proﬁ le
326 randomly assigned to placebo
325 received placebo
325 included in the safety analysis
325 included in the per-protocol analysis
324 randomly assigned to MVA85A
324 received MVA85A
324 included in the safety analysis
320 included in the per-protocol analysis
4 excluded from per-protocol analysis
 1 protocol deviation
 2 withdrew within 28 days of randomisation
 1 diagnosed with tuberculosis within 28 days of randomisation
1 was randomly assigned to placebo, 
   but received MVA85A 
1 randomly assigned to MVA85A, 
   but was not vaccinated 
650 patients randomly assigned (292 in Cape Town, 358 in Dakar)
1233 patients consented and were screened for eligibility (696 in 
           Cape Town, 537 in Dakar)
404 excluded in Cape Town
 129 were lost to follow-up or relocated
 97 had incomplete screening before study closure
 53  had active tuberculosis
 37  met other medical exclusion criteria
 24  withdrew consent before randomisation
 20  had HIV viral loads that did not meet eligibility criteria
 16  had CD4 cell counts that did not meet eligibility criteria
 16  were pregnant
 12  had an age outside the eligibility criteria
179 excluded in Dakar
 30 were lost to follow-up or relocated
 12 had incomplete screening before study closure
 2 had active tuberculosis
 5 met other medical exclusion criteria
 10 withdrew consent before randomisation
 47 had HIV viral loads that did not meet eligibility criteria
 63 had CD4 cell counts that did not meet eligibility criteria
 3 were pregnant
 4 had an age outside the eligibility criteria
 3 excluded for other reasons
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therapy; 136 (21%) had CD4 counts above 350 cells 
per μL and had never received antiretroviral therapy. 
The results of the intention-to-treat analysis were not 
diﬀ erent and are not reported. 311 (96%) participants in 
the placebo group and 298 (92%) in the MVA85A group 
received the booster vaccination. One participant was 
randomly assigned to placebo but received MVA85A; 
this participant was included in the safety population for 
MVA85A but not in the per-protocol eﬃ  cacy population. 
One participant was randomly assigned to MVA85A but 
withdrew consent before vaccination and was not 
vaccinated. This participant was excluded from both the 
safety and per-protocol populations. Baseline demo-
graphic characteristics were similar in the two study 
groups and across the two study sites (table 1; appendix). 
625 participants completed the study; 14 participants 
were lost to follow-up (nine placebo, ﬁ ve MVA85A), ﬁ ve 
withdrew consent (two placebo, three MVA85A), and six 
died (four placebo, two MVA85A).
In the per-protocol population, median follow-up was 
655 days for the 320 recipients of MVA85A and 654 days 
for the 325 placebo participants. Other than the four 
participants shown in ﬁ gure 1, all participants were 
included in the analysis.
At least one adverse event was reported in 312 (96%) 
of placebo recipients and 321 (99%) of MVA85A 
recipients (table 2). Solicited adverse events were more 
common in participants who received MVA85A than 
placebo (table 2). Most of these events were local 
injection-site reactions; other solicited adverse events 
included mild inﬂ uenza-like symptoms and regional 
lymphadenopathy. We noted no signiﬁ cant diﬀ erence 
between study groups in the frequency of serious 
adverse events. 34 serious adverse events occurred 
during the study, 17 in the placebo group and 17 in the 
Placebo (n=325) MVA85A (n=324)
Median age, years (range) 39·0 (22–41) 38·0 (21–49)
Women 255 (78%) 265 (82%)
Ethnic origin
Black 304 (94%) 302 (93%)
Mixed 21 (6%) 22 (7%)
QFT test result
Positive 150 (46%) 135 (42%)
Negative 173 (53%) 188 (58%)
Indeterminate 2 (1%) 1 (<1%)
TST result
>5 mm 128 (39%) 124 (38%)
≤5 mm 191 (59%) 190 (59%)
Missing data 6 (2%) 10 (3%)
Latent tuberculosis infection 178 (55%) 164 (51%)
5–6 months IPT before enrolment 144 (44%) 133 (41%)
Receiving antiretroviral therapy 256 (79%) 257 (79%)
CD4 count (cells per mm3)
Participants not receiving antiretroviral therapy 564 (169·8) 571 (187·5)
Participants receiving antiretroviral therapy 599 (199·6) 598 (220·7)
HIV viral load (copies per mL)
Participants not receiving antiretroviral therapy 41 371 (92 456·9) 62 168 (166 912·1)
Participants receiving antiretroviral therapy 29 (27·1) 34 (63·7)
Data are n (%) or mean (SD), unless otherwise stated. QFT=QuantiFERON-TB Gold In-Tube. TST=tuberculin skin test. 
IPT=isoniazid preventive therapy.
 Table 1: Demographic and baseline characteristics (safety analysis population)
Overall Participants not receiving antiretroviral 
therapy
Participants receiving antiretroviral 
therapy
Placebo 
(n=325)
MVA85A 
(n=324)
Diﬀ erence 
(MVA85A 
minus 
placebo) 
(95% CI)
Placebo 
(n=69)
MVA85A 
(n=67)
Diﬀ erence 
(MVA85A 
minus 
placebo) 
(95% CI)
Placebo 
(n=256)
MVA85A 
(n=257)
Diﬀ erence 
(MVA85A 
minus 
placebo) 
(95% CI)
Any adverse event 312
(96·0%; 
93·3–97·7)
321
(99·1%; 
97·3–99·7)
3·1
(0·7 to 5·4)
67
(97·1%; 
90·0–99·2)
66
(98·5%; 
92·0–99·7)
1·4
(–3·5 to 6·3)
245
(95·7%; 
92·5–97·6)
255
(99·2%; 
97·2–99·8)
3·5
(0·8 to 6·2)
Solicited adverse event 235
(72·3%; 
67·2–76·9)
288
(88·9%; 
85·0–91·9)
16·6
(10·6 to 22·5)
50
(72·5%; 
61·0–81·6)
63
(94·0%; 
85·6–97·7)
21·6
(9·6 to 33·5)
185
(72·3%; 
66·5–77·4)
225
(87·5%; 
83·0–91·0)
15·3
(8·5 to 22·1)
Serious adverse event 17
(5·2%; 
3·9–8·2)
17
(5·2%; 
3·3–8·2)
0·02
(–3·4 to 3·4)
2
(2·9%; 
0·8–10·0)
9
(13·4%; 
7·2–23·6)
10·5
(1·5 to 19·6)
15
(5·9%; 
3·6–9·4)
8
(3·1%; 
1·6–6·0)
–2·7
(–6·3 to 0·8)
Related adverse event 307
(94·5%; 
91·4–96·5)
318
(98·1%; 
96·0–99·2)
3·7
(0·8 to 6·6)
66
(95·7%; 
88·0–98·5)
66
(98·5%; 
92·0–99·7)
2·9
(–2·8 to 8·5)
241
(94·1%; 
90·6–96·4)
252
(98·1%; 
95·5–99·1)
3·9
(0·6 to 7·2)
Severe adverse event 84
(25·8%; 
21·4–30·9)
100
(30·9%; 
26·1-36·1)
5·0
(–1·9 to 11·9)
15
(21·7%; 
13·6–32·8)
22
(32·8%; 
22·8–44·8)
11·1
(–3·8 to 26)
69
(27·0%; 
21·7–32·9)
78
(30·4%; 
25·1–36·2)
3·4
(–4·4 to 11·2)
Data are n (%; 95% CI), unless otherwise stated. Serious adverse events were coded with Medical Dictionary for Regulatory Activities version 14.0. Patients with multiple 
events in each category are counted only once in each category.
Table 2: Overview of adverse events (safety analysis population)
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MVA85A group (table 2; appendix). All but one of these 
events were judged to be unrelated to vaccination; a 
case of probable tuberculous meningitis that occurred 
6 days after vaccination was judged to be possibly 
related to vaccination. The data monitoring committee 
reviewed this case, did not request unmasking, and 
recommended continuing with the study. The 
participant was treated for tuberculous meningitis and 
made a full recovery. At study completion, this 
participant was identiﬁ ed as having received MVA85A. 
13 serious adverse events in the infections and 
infestations category occurred during the study (the 
Figure 2: Vaccine immunogenicity (both study sites combined)
(A) Antigen 85A (Ag85A) interferon γ enzyme-linked immunospot analysis responses. Data are presented as spot-forming cells (SFC) per million peripheral blood mononuclear cells (PBMCs). p values 
were calculated with Wilcoxon matched-pair signed-rank tests. Box and whisker plots show median, IQR, and minimum and maximum values. (B) Whole blood intracellular cytokine staining assay of 
total cytokines. Data are presented as frequency of CD4 and CD8 T cells producing cytokines. Box and whisker plots show median, IQR, and minimum and maximum values. IFNγ=interferon γ. 
TNFα=tumour necrosis factor α. IL=interleukin. V1=vaccination 1. V2=vaccination 2.
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only category with more than ﬁ ve serious adverse 
events in either group), eight in the placebo group and 
ﬁ ve in the MVA85A group; this diﬀ erence was not 
signiﬁ cant (Fisher’s exact test, p=0·58).
The frequency of severe adverse events did not diﬀ er 
signiﬁ cantly between study groups (table 2). We noted no 
signiﬁ cant changes in CD4 cell count or HIV-1 viral load 
throughout the course of the trial in either study group 
(data not shown). Routine haematological and 
biochemical test results did not diﬀ er between study 
groups (data not shown).
ELISPOT responses to Ag85A were signiﬁ cantly higher 
in participants from Dakar than in those from Cape Town 
at baseline (p=0·0016), but at no other timepoint. This 
diﬀ erence was not seen with the less sensitive whole 
blood intracellular cytokine staining assay. MVA85A 
induced an Ag85A-speciﬁ c T-cell response that peaked 
7 days after the ﬁ rst and booster vaccinations (median 
spots per million: day 0 [ﬁ rst vaccination], 9·0 [IQR 
2·3–51·0]; day 7 [ﬁ rst vaccination], 337·0 [139·3–993·8]; 
day 0 [booster vaccination], 103·5 [14·8–223·8]; day 7 
[booster vaccination], 426·0 [150·0–745·0]; ﬁ gure 2). 
Responses at each timepoint after vaccination did not 
diﬀ er by study site or by antiretroviral therapy status. 
Medians in the placebo group did not exceed 20 spots per 
million at any timepoint.
Whole blood intracellular cytokine staining showed the 
most commonly measured cytokine from CD4 T cells was 
interferon γ, in agreement with the ELISPOT data. 
Tumour necrosis factor α and low concentrations of 
interleukins 2 and 17 were also detected (table 3, ﬁ gure 2). 
Overall, numbers of antigen-speciﬁ c CD8 T cells were 
very low and were only positive for interferon γ and 
tumour necrosis factor α. Multiparameter ﬂ ow-cytometric 
analysis showed that mainly monofunctional Ag85A-
speciﬁ c CD4 T cells were present before and after 
vaccination (ﬁ gure 3). Ag85A-speciﬁ c antibody responses 
were less than twice the baseline value after vaccination 
in all but three participants.
In the per-protocol population, the overall number of 
tuberculosis cases and incidence during study follow-up 
of tuberculosis cases (endpoint 1) was six (2%) in the 
MVA85A group and nine (3%) in the placebo group, for 
a vaccine eﬃ  cacy of 32·8% (95% CI –111·5 to 80·3; 
table 4). Figure 4 shows the Kaplan-Meier time-to-
disease analysis for endpoint 1. Stratiﬁ cation by 
antiretroviral therapy status showed no signiﬁ cant 
diﬀ erence between treatment groups. Eight of the 
15 endpoint 1 cases were QFT positive at enrolment. No 
additional participants met endpoint 2 who did not 
already meet endpoint 1. Vaccine eﬃ  cacy for endpoint 3 
was 10·5% (–161·3 to 70.0). Disease incidence did not 
diﬀ er by site. Median time to diagnosis of endpoint 1 
was 249 days in the MVA85A group and 236 days in the 
placebo group. 159 (50%) of 320 MVA85A recipients 
and 148 (46%) of 325 placebo recipients were investigated 
for tuberculosis during the study. The study was 
insuﬃ  ciently powered to assess the eﬃ  cacy of MVA85A 
for the prevention of tuberculosis disease in the subset 
of participants receiving antiretroviral therapy or 
isoniazid prophylaxis. The absence of eﬃ  cacy also made 
it impossible to identify potential immunological 
correlates of protection from tuberculosis in participants 
vaccinated with MVA85A.
The number of QFT-negative participants who 
converted to QFT positive by the end of the study was 38 
(20%) in the MVA85A group and 40 (23%) in the placebo 
group, for a vaccine eﬃ  cacy of 11·7% (95% CI –41·3 to 
MVA85A (n=28) MVA85A timepoint comparisons (p values) Placebo (n=29)
Day 0 
(vaccination 
1)
Day 7 
(vaccination 
1)
Day 0 
(vaccination 
2)
Day 7 
(vaccination 
2)
Day 0 
(vaccination 
1) vs day 7 
(vaccination 
1)
Day 0 
(vaccination 
1) vs day 0 
(vaccination 
2)
Day 0 
(vaccination 
1) vs day 7 
(vaccination 
2)
Day 0 
(vaccination 
2) vs day 7 
(vaccination 
2)
Day 0 
(vaccination 
1)
Day 7 
(vaccination 
1)
Day 0 
(vaccination 
2)
Day 7 
(vaccination 
2)
CD4 IFNγ 0·01
(0–0·07)
0·1
(0–1·12)
0·03
(0–0·28)
0·11
(0·02–0·82)
<0·0001 0·0015 <0·0001 <0·0001 0·02
(0–0·12)
0·01
(0–0·08)
0
(0–0·08)
0·01
(0–0·18)
CD4 TNFα 0·02
(0–0·12)
0·11
(0–0·53)
0·05
(0–0·57)
0·11
(0–0·46)
<0·0001 0·0403 <0·0001 <0·0001 0·02
(0–0·15)
0·02
(0-0·14)
0·02
(0–0·11)
0·02
(0–0·23)
CD4 IL-2 0·021
(0–0·11)
0·07
(0–0·68)
0·04
(0–0·27)
0·1
(0·03–0·44)
<0·0001 0·0421 <0·0001 <0·0001 0·02
(0–0·08)
0·017
(0–0·08)
0·02
(0–0·09)
0·018
(0–0·06)
CD4 IL-17 0·09
(0·01–0·28)
0·12
(0·03–0·27)
0·09
(0–0·37)
0·1
(0·03–0·23)
0·0946 0·5425 0·4047 0·2843 0·07
(0–0·27)
0·06
(0·02–0·27)
0·08
(0·01–0·26)
0·078
(0–0·25)
CD8 IFNγ 0
(0–0·21)
0·02
(0–0·94)
0
(0–0·58)
0·01
(0–0·3)
0·0101 0·5499 0·2264 0·2897 0
(0–0·35)
0
(0–0·19)
0
(0–0·33)
0
(0–0·24)
CD8 TNFα 0
(0–0·28)
0
(0–0·24)
0
(0–0·48)
0
(0–0·05)
0·4513 0·7615 0·7337 0·3953 0
(0–0·09)
0
(0–0·38)
0
(0–0·2)
0
(0–0·13)
Data are median (minimum to maximum) of total cytokines at each of the study timepoints, unless otherwise stated. Population is the immunology substudy (the ﬁ rst 70 participants), of which complete data 
were available for 57 participants. Statistical comparison of total cytokine responses in MVA85A study group used Wilcoxon matched-pairs signed-rank test. IL=interleukin. IFNγ=interferon γ. TNFα=tumour 
necrosis factor α.
 Table 3: Total intracellular cytokine response, presented as frequency of CD4 T cells and CD8 T cells producing speciﬁ c cytokines
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44·9). QFT conversion did not diﬀ er by antiretroviral 
therapy status (data not shown), but it did diﬀ er by site. 
In Cape Town, 41 (31%) of 132 participants converted, 
whereas in Dakar, 37 (16%) of 227 converted (χ² 10·89, 
p=0·001). Frequency of QFT reversion (participants who 
were positive at baseline and negative at end of study) 
was similar in the two treatment groups (17 [14%] of 124 
for MVA85A and 27 [19%] of 139 for placebo; p=0·22), 
and did not diﬀ er by antiretroviral therapy status (data 
not shown). Tuberculin skin test conversion was not a 
prespeciﬁ ed endpoint and is not reported here, but will 
be the subject of further analysis.
Overall Participants not receiving antiretroviral 
therapy
Participants receiving antiretroviral 
therapy
Placebo MVA85A Vaccine eﬃ  cacy 
(95% CI)
Placebo MVA85A Vaccine eﬃ  cacy 
(95% CI)
Placebo MVA85A Vaccine eﬃ  cacy 
(95% CI)
Disease endpoint 1 
(primary eﬃ  cacy endpoint)
9/325
(2·8%)
6/320
(1·9%)
32·8%
(–111·5 to 80·3)
1/69
(1·4%)
2/65
(3·1%)
–114·1%
(–12 528·3 to 88·9)
8/256
(3·1%)
4/255
(1·6%)
50·3%
(–85·4 to 89·1)
Disease endpoint 3 9/325
(2·8%)
8/320
(2·5%)
10·5%
(–161·3 to 70·0)
1/69
(1·4%)
3/65
(4·6%)
–224·7%
(–16 947·7 to 73·9)
8/256
(3·1%)
5/255
(2·0%)
38·2%
(–114·1 to 84·1)
QFT positive conversion 40/173
(23·1%)
38/186
(20·4%)
11·7%
(–41·3 to 44·9)
11/36
(30·6%)
6/38
(15·8%)
44·2%
(–64·8 to 83·0)
29/137
(21·2%)
32/148
(21·6%)
–0·1%
(–71·5 to 41·4)
Data are n/N (%), unless otherwise stated. Disease endpoint 1 was deﬁ ned as culture or GeneXpert MTB/RIF positivity; disease endpoint 2 included endpoint 1 and a 
composite clinical endpoint; and disease endpoint 3 was commencement on anti-tubercular chemotherapy. No additional participants met endpoint 2 who did not already 
meet endpoint 1. QFT=QuantiFERON-TB Gold In-Tube.
 Table 4: Primary and secondary eﬃ  cacy results (per-protocol population)
Figure 3: Polyfunctional CD4 T cells
Plots show frequency of CD4 T cells producing combinations of the studied cytokines. Bars are median values and dots represent individual volunteers. IFNγ=interferon γ. TNFα=tumour necrosis 
factor α. IL=interleukin. V1=vaccination 1. V2=vaccination 2.
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Discussion
This phase 2 trial in 650 adult participants infected with 
HIV-1 showed that MVA85A was well tolerated and 
immunogenic, with safety and immunogenicity proﬁ les 
similar to those reported elsewhere for other populations 
in which this candidate vaccine has been assessed.10–14 
However, we did not identify any signiﬁ cant eﬃ  cacy 
against tuberculosis disease or M tuberculosis infection.
Both ﬁ rst and booster vaccination with MVA85A induced 
a signiﬁ cant increase in Ag85A-speciﬁ c T cells. Responses 
did not diﬀ er by antiretroviral therapy status. A probable 
explanation for this ﬁ nding is the high baseline median 
CD4 count (571 cells per mm³; table 1, appendix) in 
participants who had not received antiretroviral therapy. 
Unlike the previously reported infant eﬃ  cacy trial of 
MVA85A,10 baseline ELISPOT responses were detected in 
this trial and were signiﬁ cantly higher in participants from 
Dakar than in those from Cape Town. This result might be 
due to greater exposure to environmental mycobacteria; 
and the ﬁ nding is unlikely to be due to a technical issue 
because it was only recorded at this timepoint, and there 
was a robust quality control programme in place for these 
assays. Furthermore, the median response 7 days after 
vaccination in this trial exceeded that seen in the infant 
trial (337 vs 136 spots per million).10 Additionally, the 
functional phenotype of the dominant T-cell population in 
this trial was monofunctional by contrast with the infant 
trial, in which the dominant phenotype was polyfunctional.10 
In both trials, the recorded response was insuﬃ  cient to be 
associated with protection. It is not clear whether a 
quantitatively greater or a qualitatively diﬀ erent immune 
response is needed for protection. Alternative approaches, 
including the delivery of candidate vaccines direct to the 
respiratory mucosa, might be more potent routes of 
immunisation. For example, we have previously reported 
that delivery of MVA85A by aerosol to HIV-negative, BCG-
vaccinated adults in the UK is well tolerated and induces 
potent mucosal and systemic immunity.26 Further 
assessment is needed before this route can be examined in 
countries with a high burden of tuberculosis. This 
approach, together with other strategies to improve the 
immunogenicity of MVA85A, are currently under 
investigation.
The recorded annual incidence of tuberculosis (endpoint 
1) was substantial (1·43% across treatment groups) and 
did not diﬀ er between sites. However, this incidence was 
lower than previously reported in Cape Town.27 The 
numbers of participants receiving antiretroviral therapy 
was greater than originally envisaged, because of the 
increased availability of this therapy during the study 
period and the change in national and international 
guidelines on the provision of antiretroviral therapy. 
These factors, combined with the redesign of this study 
upon availability of the infant trial results,10 led to a 
reduction in statistical power to detect a diﬀ erence in 
tuberculosis disease incidence between treatment groups, 
leading to wide CIs for our estimates of vaccine eﬃ  cacy.
In this trial, the incidence of infection determined by 
QFT conversion was much higher than the incidence of 
tuberculosis disease, so CIs around the estimates of 
eﬃ  cacy against infection are narrower. The overall 
recorded annual QFT conversion rate of about 12% 
meant that we had about 80% power to detect a vaccine 
eﬃ  cacy of 50% against M tuberculosis infection. In view 
of the cost and complexity of human eﬃ  cacy studies, 
there is now increased focus on infection as an endpoint 
rather than disease in proof-of-concept studies before 
progression to prevention-of-disease eﬃ  cacy trials.9 
However, this approach presupposes that the immune 
mechanisms needed to prevent infection and disease 
are similar. Our poor understanding of the biology 
underlying dynamic QFT conversion and reversion 
further complicates this shift in emphasis. The rate of 
QFT reversion was almost as high as the rate of 
conversion: whether this ﬁ nding represents a true 
biological eﬀ ect or technical variability in the assay 
cannot be determined from these data.
In this study, we have shown that high-quality, 
multicentre tuberculosis vaccine trials are possible in 
Africa, and have succeeded in the characterisation of the 
epidemiology of tuberculosis associated with HIV-1 in two 
African cities. Nevertheless, the disappointing ﬁ nding 
with respect to vaccine eﬃ  cacy for MVA85A suggests the 
need for standardised preclinical animal models that better 
represent human disease and an improved understanding 
of immune mechanisms of protection in human 
tuberculosis. Such advances would greatly enhance the 
ability to eﬃ  ciently translate clinical research capacity into 
the development and deployment of an eﬀ ective vaccine.
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Figure 4: Cumulative incidence of diagnosis of tuberculosis endpoint 1 by treatment group
Endpoint 1 was deﬁ ned as a positive ﬁ nding from culture or GeneXpert MTB/RIF assay. 
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